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BACKGROUND: BAL101553 (lisavanbulin), the lysine prodrug of BAL27862 (avanbulin), exhibits broad anti-proliferative activity in
human cancer models refractory to clinically relevant microtubule-targeting agents.
METHODS: This two-part, open-label, phase 1/2a study aimed to determine the maximum tolerated dose (MTD) and dose-limiting
toxicities (DLTs) of 2-h infusion of BAL101553 in adults with advanced or recurrent solid tumours. The MTD was determined using a
modified accelerated titration design in phase I. Patients received BAL101553 at the MTD and at lower doses in the phase 2a
expansion to characterise safety and efficacy and to determine the recommended phase 2 dose (RP2D).
RESULTS: Seventy-three patients received BAL101553 at doses of 15–80mg/m2 (phase 1, n= 24; phase 2a, n= 49). The MTD was
60mg/m2; DLTs observed at doses ≥60mg/m2 were reversible Grade 2–3 gait disturbance with Grade 2 peripheral sensory
neuropathy. In phase 2a, asymptomatic myocardial injury was observed at doses ≥45mg/m2. The RP2D for 2-h intravenous infusion
was 30 mg/m2. The overall disease control rate was 26.3% in the efficacy population.
CONCLUSIONS: The RP2D for 2-h infusion of BAL101553 was well tolerated. Dose-limiting neurological and myocardial side effects
were consistent with the agent’s vascular-disrupting properties.
CLINICAL TRIAL REGISTRATION: EudraCT: 2010-024237-23.
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BACKGROUND
Microtubules are present in both interphase- and dividing cells
and are involved in several critical cellular functions, including
mitosis, intracellular trafficking, cell signalling, migration, secre-
tion, and angiogenesis.1–3 Microtubule-targeting agents (MTAs)
can disrupt microtubule and mitotic spindle function, with
subsequent anti-tumour and vascular-disrupting effects. Conven-
tional MTAs fall into two main groups: microtubule-destabilising
agents (including Vinca alkaloids, halichondrins, and combretas-
tatins) that destabilise or depolymerise microtubules, and
microtubule-stabilising agents (including taxanes and epothi-
lones) that polymerise microtubules.3,4 At the cellular level, both
groups of agents suppress spindle-microtubule dynamics, causing
mitotic arrest, and trigger cell death through apoptosis.3
Microtubule-targeting agents are among the most active
cytotoxic anti-cancer drugs currently in use. However, despite a
high initial sensitivity of many malignancies to MTAs, resistance
invariably arises through several mechanisms that are postulated
to include drug efflux pump (P-glycoprotein) overexpression,
aberrant expression of tubulin isotypes and BRCA1, and
deregulated cell survival pathways.3,5–7 There is an urgent clinical
need for novel treatment options for patients with advanced solid
tumours, who are refractory to conventional MTAs.
BAL101553 (lisavanbulin) is a water-soluble lysine prodrug of
the active furazano-benzimidazole derivative BAL27862 (avanbu-
lin), a novel, synthetic molecule that shows promising anti-tumour
activity.8,9 Non-clinical studies have revealed that BAL27862 acts
by destabilising microtubules through a unique mechanism of
action distinct from that of other MTAs, arresting tumour cell
proliferation in the G2/M phase of the cell cycle and inducing
apoptosis.9,10 BAL27862 shares the intradimer interface, a tubulin
binding site, with colchicine and disrupts microtubule organisa-
tion thereby inducing the formation of the ‘spindle assembly
checkpoint’.9,10
BAL101553 has demonstrated broad anti-tumour activity across
a panel of cell lines and xenograft models.11–20 Importantly,
BAL101553 is active in human cancer models that are refractory to
standard of care therapeutics, including clinically relevant MTAs,
due to P-glycoprotein overexpression and non-P-glycoprotein-
related mechanisms.14,15,20 Hence, the activity of BAL101553 does
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not appear to be affected by factors that confer resistance to
conventional MTAs. BAL101553 also targets the tumour micro-
environment14 causing tumour vascular disruption,21 which has
also been described for other MTAs. BAL101553 can be
administered intravenously or orally.
Here, we report results from the first-in-human dose-escalation
study of BAL101553 monotherapy in patients with advanced
cancer.
METHODS
Study design
This was a two-part, open-label, phase 1/2a study of single-agent
BAL101553 in patients with advanced solid tumours. The study
was conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice. Institutional Review Boards at the four
study sites in the UK approved the study and all participants
provided written informed consent.
The primary objectives were to determine the maximum
tolerated dose (MTD) and characterise the dose-limiting toxicities
(DLTs) of single-agent BAL101553 administered intravenously over
2 h on days 1, 8, and 15 of a 28-day treatment cycle. Secondary
objectives comprised evaluation of the safety and tolerability of
BAL101553, the pharmacokinetics (PK) of BAL101553 and
BAL27862, and the anti-tumour activity of BAL101553. Exploratory
objectives were to characterise the pharmacodynamic effects of
BAL101553/BAL27862, including functional vascular imaging, and
to explore the potential utility of biomarkers in blood and/or
tumour tissue for patient stratification.
The MTD of BAL101553 was determined by dose-escalation in
the phase 1 part of the study. The phase 2a expansion part was
originally intended to characterise the safety, tolerability, and
efficacy of BAL101553 at the MTD level determined in phase 1.
Based on emergent data during the study, the design of the phase
2a part was modified in several amendments to investigate
whether a lower dose level was clinically preferable to dosing at
the MTD. The design was changed from a fixed-dose treatment of
20 patients at the MTD to an open-label randomised (1:1) design
that randomised 40 patients to receive either the MTD or 50% of
the MTD. Randomisation of patients during this period of the
study is described in Supplementary Text 1. In subsequent
amendments the tested doses were further reduced and
ultimately all remaining patients were treated at the 50% MTD
dose level.
Patients
Eligible patients were aged 18 years or older with advanced or
recurrent solid tumours who had failed standard therapy, or for
whom no standard therapy was available. Patients who had
received previous treatment with taxanes or other MTAs were
permitted. In the phase 2a part of the study, inclusion was limited
to patients with colorectal, gastric, or gastro-oesophageal junction,
non-small-cell lung, ovarian (including primary peritoneal), pan-
creatic (including ampullary), or triple-negative breast cancers to
limit variability. These six cancer types were selected based on
clinical and/or pharmacodynamic efficacy signals in the phase 1
part of the study, and biomarker studies of human tumour tissue
libraries suggested that these cancers typically express biomarkers
considered relevant for the anti-tumour efficacy of BAL101553, i.e.,
microtubule- and spindle assembly checkpoint-related markers
(such as BubR1).
BuBR1 staining was performed in available tissues from patients
participating in this study. However, these were exploratory
studies and not performed as a selection biomarker prior to study
entry (data not shown).
All patients had measurable disease according to RECIST
(Response Evaluation Criteria In Solid Tumours) criteria v1.1
documented within 35 days prior to starting study drug: an
Eastern Cooperative Oncology Group (ECOG) performance sta-
tus ≤ 1; adequate organ and marrow function; and a life
expectancy of ≥12 weeks.
Patients with peripheral neuropathy Grade ≥ 2 (National Cancer
Institute Common Terminology Criteria for Adverse Events [NCI-
CTCAE] v4.03); systolic blood pressure ≥ 140mmHg and/or dia-
stolic BP ≥ 90mmHg; significant cardiac or cerebrovascular
disease; those treated with a calcium channel blocker, or who
required a combination of more than two antihypertensive
medications to control blood pressure and patients requiring
vitamin K antagonists were excluded from study entry. Full
inclusion/exclusion criteria are listed in Supplementary Text 2.
Study treatment
BAL101553 was administered intravenously over 2 h on days 1, 8,
and 15 of a 28-day cycle. Intravenous dosing was used as the oral
formulation of BAL101553 was not available at the time of this
study. Dosing on days 1, 8, and 15 over a 28-day cycle was chosen
based on the expected gastrointestinal and haematological
toxicity (observed in 3-week Good Laboratory Practice toxicity
studies in rats and dogs with weekly intravenous administration),
with the goal to have a 14-day drug-free interval to recover from
such toxicity. Treatment was continued until disease progression,
unacceptable toxicity or until investigator/patient decision to
withdraw.
Intra-patient dose escalation to a higher dose already con-
sidered safe was allowed in the phase 1 part of the study for
patients who had completed two or more cycles of BAL101553
without any Grade ≥ 2 drug-related adverse events (AEs). Dose
interruptions were allowed for a DLT until recovery to CTCAE
Grade ≤ 1 or baseline; subsequent doses of BAL101553 were
reduced by one dose level. Dose interruptions and reductions
were also allowed for non-DLT events. For cycle 1, if a patient did
not meet the requirements for being dosed on either day 8 or day
15, the physician could delay treatment for up to 5 days.
BAL101553 was administered if the patient met re-treatment
criteria within these 5 days. Cycle 1 was regarded as complete if all
three doses of BAL101553 were administered within 28 days, with
recovery of any toxicity to permit initiation of cycle 2 with a
maximum delay of 14 days.
Dose escalation. The starting weekly dose of BAL101553 (15mg/
m2) was based on Good Laboratory Practice toxicology studies in
dogs and was approximately 1/6th of the highest non-severely toxic
dose observed in these studies. This corresponded to a dose of
approximately 27.5mg of BAL101553 for a 1.73m2, 70-kg patient.
Full details of the dosing criteria are presented in Supplementary
Table 1. Dose escalation in the Phase 1 part of the study was
performed using a modified accelerated 3+ 3 titration design.
Patients were enrolled in sequential dose cohorts comprising one to
six patients; cohorts were expanded if a patient experienced a
BAL101553 treatment-related DLT during cycle 1. DLTs were
generally defined as Grade ≥ 4 haematological AEs or Grade≥ 3
non-haematological AEs (full DLT criteria are defined in Supplemen-
tary Text 3).
Dose cohort escalation decisions incorporated clinical review of all
relevant available data from contemporaneous and previous dose
cohorts. The maximum administered dose was defined as the dose
level at which a DLT was observed during treatment cycle 1 in ≥33%
of evaluable patients. The MTD was defined as the highest dose
level below the maximum administered dose with an acceptable
tolerability profile. The recommended phase 2 dose (RP2D) was
determined based on all available safety, PK, pharmacodynamic, and
efficacy data.
Study assessments
Safety. Safety was assessed throughout the study. Assessments
included recording of all AEs (according to NCI-CTCAE v4.03) and
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serious AEs (SAEs), laboratory parameters, echocardiography, vital
signs, ECOG performance status, physical examination, radiology
assessments, and evaluation of concomitant medications.
Pharmacokinetics. Blood samples for assessment of BAL101553
and BAL27862 pharmacokinetics were taken from patients in
phase 1 of the study on day 1 of cycles 1 and 2 (pre-dose, and at 1,
2 [immediately prior to end of infusion], 2.5, 3, 4, 6, 8, 24, and 48 h
after the start of the 2-h infusion). In the phase 2a part of the
study, samples were taken on day 1 of cycle 1 (pre-dose, 2
[immediately prior to end of infusion], 4, 6, 10, and 24 h after the
start of the 2-h infusion). Additional samples were taken
immediately prior to the end of the 2-h infusion on days 8 and
15 of cycle 1 (and cycle 2 in phase 1), at the occurrence of a DLT,
and from patients undergoing intra-patient dose escalation or
dose reduction. Urine samples were taken on day 1 of cycles 1 and
2 from patients in the phase 1 part of the study for calculation of
total 24-h urinary excretion of BAL101553 and BAL27862.
BAL101553 and BAL27862 were quantified in plasma and urine
using liquid chromatography tandem-mass spectrometry with a
lower limit of quantification of 1 ng/mL.
Pharmacodynamics. Blood samples obtained on days 1, 15, and
22 of cycle 1, and day 22 of cycle 2 were evaluated for circulating
tumour cell, circulating endothelial cell, and circulating endothelial
progenitor cell counts. Tumour biopsies (where possible) were to
be taken at screening, on day 22 of cycles 1, 2, and one
subsequent cycle, and at disease progression. Tumour biopsies
were analysed by immunohistochemistry for exploratory patient
biomarkers. In phase 2a, serial dynamic contrast-enhanced
magnetic resonance imaging (MRI) and diffusion-weighted MRI
were conducted in suitable patients to assess the effect of
BAL101553 on tumour vascularity and cellularity. Imaging was
conducted at two pre-treatment visits (2–3 days apart) and three
post-treatment visits (days 1, 2, and 8 of cycle 1).
Efficacy. Tumour response was assessed using computed tomo-
graphy scans according to RECIST v1.1 every two cycles (8 weeks)
in patients with measurable disease.
Statistical analyses
Study populations. The modified accelerated 3+ 3 design and
the exploratory nature of the phase 2a expansion portion did not
require sample size calculation justification.
Patients eligible for determining the MTD had to have received
all three doses of BAL101553 during cycle 1 (or at least one dose if
the patient experienced a DLT) and been followed for ≥28 days
after the first dose for safety (MTD population). Safety was
evaluated in all recruited patients (safety population). Pharmaco-
kinetics were evaluated in all patients who received at least one
partial or complete dose of BAL101553 and had at least one post-
baseline PK assessment (PK population). Anti-tumour activity was
evaluated in all patients who received all three doses of
BAL101553 in cycle 1 and who either underwent at least one
on-study tumour assessment or a radiological assessment by
RECIST guidelines at or after the end of cycle 2, or who showed
clinical and/or radiological progressive disease prior to the end of
cycle 2 (efficacy population). Efficacy parameters were also
analysed using the full analysis population (all patients who
received at least one partial or complete dose of BAL101553 based
on the intent-to-treat principle).
Statistical assessments. Demographic, baseline, safety, PK, and
pharmacodynamic data were analysed by dose cohort using
descriptive statistics. Pharmacokinetic parameters were calculated
from plasma and urine concentration data by non-compartmental
analysis using Phoenix WinNonLin 7.0. Anti-tumour activity was
assessed by dose cohort summarising the objective response rate
(ORR), disease control rate (DCR), and progression-free survival
(PFS) with exact 95% confidence intervals (CI). The ORR was
defined as complete response plus partial response (PR); the DCR
was defined as complete response plus PR plus stable disease (SD)
lasting two or more cycles from start of BAL101553 treatment to
earliest date of clinical/objective progression. Progression-free
survival was defined as the interval between the date of first
infusion and the earliest date of clinical/objective progression or
death. Median time to progression or death was also determined
by the Kaplan−Meier method.
RESULTS
Patient demographics and disposition
Seventy-three patients were enrolled at four sites in the UK. The
first patient, first visit was on 12 July 2011 and the last patient, last
visit was on 6 April 2016. Baseline demographic and disease data
are presented in Table 1 and by dose group in Supplementary
Table 2. Overall, 53.4% of patients were male, 90.4% were white
Caucasian and median age was 59 years (range 29–80). ECOG
performance status at baseline was 0 for 23 (31.5%) patients and 1
for 50 (68.5%) patients. The most prevalent cancer types were
colorectal cancer (30.1%), non-small-cell lung cancer (12.3%), and
pancreatic/ampullary cancer (12.3%). Thirty-four (46%) patients
had previously been treated with MTAs, of which 24 had
discontinued treatment due to documented disease progression.
Phase 1
All patients were treated with at least one dose of BAL101553 at
dose levels between 15 and 80mg/m2. Twenty-four patients
received BAL101553 at starting dose levels of 15 mg/m2 (n= 1),
30 mg/m2 (n= 3), 45 mg/m2 (n= 3), 60 mg/m2 (n= 10), and 80
mg/m2 (n= 7). Two of six evaluable patients treated at a starting
dose of 80 mg/m2 experienced a DLT of reversible Grade 2–3 gait
disturbance. The gait disturbance in both cases occurred with fully
or partially reversible Grade 2 peripheral sensory neuropathy. The
reduction in proprioception/sensation contributed to the gait
disturbance. Therefore, the MTD for BAL101553 administered as a
2-h infusion on days 1, 8, and 15 of a 28-day cycle was determined
to be 60mg/m2 and the maximum administered dose was 80 mg/
m2. One of the six evaluable patients treated at the MTD
experienced a similar toxicity (Grade 3 reduced mobility with
dizziness).
Phase 2a
Following the changes in study design, patients were randomised
to receive BAL101553 in the phase 2a part at either the MTD (60
mg/m2) or 50% of the MTD (30mg/m2). Three additional AEs
meeting the criteria for a DLT were reported in the phase 2a part
of the study. These events necessitated that the maximum dose
investigated in phase 2a was reduced to 45mg/m2 after two
patients treated at 60 mg/m2 experienced myocardial injury
(Grade 3 troponin elevation and electrocardiogram changes
including T-wave inversions). Subsequently, a further patient
treated at 45 mg/m2 experienced asymptomatic myocardial
infarction and the dose cohort level was lowered to 30mg/m2.
Overall, 49 patients received BAL101553 at starting dose levels of
30mg/m2 (n= 33), 45 mg/m2 (n= 5), and 60mg/m2 (n= 11) in
the phase 2a expansion part. The RP2D for 2-h intravenous
infusion of BAL101553 was determined to be 30mg/m2.
Overall safety data
The median duration of study-drug treatment was 43.0 days
(range 1–1032) and two cycles (range 1–37). Four (5.5%) patients
withdrew consent: two due to DLTs, one due to the time-intensive
schedule of the trial, and one for whom no reason was given. Six
(8.2%) patients died during the study or within 30 days following
the last dose. One patient died during screening and was never
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dosed. The other five deaths occurred within 28 days of the last
study drug administration; four were due to disease progression
and judged not to be drug related. One patient (30 mg/m2
BAL101553) died due to a suspected unexpected serious adverse
reaction of acute abdomen, which, although primarily attributed
to cancer progression (gastro-oesophageal junction carcinoma
with liver metastases), was assessed as possibly related to
BAL101553.
Adverse events judged to be drug-related occurred in 65
(89.0%) patients (Table 2). The most common were nausea
(43.8%), vomiting (34.2%), hypertension (32.9%), fatigue (31.5%),
diarrhoea (30.1%), peripheral neuropathy (17.8%), and
decreased appetite (17.8%). Twenty-two (30.1%) patients
experienced 69 treatment-related and dose-dependent severe
(Grade 3−4) events. Hypertension was the most common Grade
3−4 treatment-related AE, occurring in 18 (24.7%) patients. Five
out of seven (71.4%) evaluable patients in the 80 mg/m2 cohort
and 10 out of 21 (47.6%) patients in the 60 mg/m2 cohort
experienced Grade 3/4 hypertension. Only one (2.8%) patient
treated at the RP2D (30 mg/m2) experienced Grade 3
hypertension.
Serious AEs were reported in 36 (49.3%) patients. Sixteen SAEs
were considered possibly or probably treatment-related in 13
(17.8%) patients. Pyrexia (n= 3), tumour pain (n= 3), hypertension
(n= 2), and acute coronary syndrome/myocardial infarction (n= 2)
were the only treatment-related SAEs to occur in more than one
patient.
Thirteen (17.8%) patients discontinued due to AEs including five
(6.8%) patients for whom the AE was considered to be treatment
related. Only one AE led to study drug discontinuation in more
than one patient, intestinal obstruction which occurred in three
(4.1%) patients treated at 30, 60, and 80mg/m2, none of which
were judged to be related to the study drug. Overall, 22 (30.1%)
patients experienced treatment-emergent AEs that led to dose
interruptions or modifications.
There was no apparent difference in the proportion of patients
experiencing AEs when stratified by prior MTA exposure or not,
and no significant odds ratio observed for any of the treatment-
emergent AEs between the groups (data not shown).
Pharmacokinetics
Seventy-three patients were evaluable for PK on cycle 1, day 1,
and 21 patients on cycle 2, day 1. The low number of evaluable
patients on cycle 2, day 1 was due to patient discontinuations
during cycle 1 due to either progressive disease or adverse events.
Overall, the exposure of BAL101553 and BAL27862 was dose
related (Fig. 1a, b, Supplementary Fig. 1A, B) and similar between
male and female patients (Supplementary Fig. 2A, B).
The prodrug BAL101553 was rapidly converted to BAL27862 in
all subjects and at all doses. In the RP2D (30mg/m2) cohort, the
BAL101553 prodrug had a moderate plasma clearance (CL:
geometric mean 19.3 L/h) and low volume of distribution (Vss:
20.1 L), resulting in a short half-life (1.96 h). The active drug
BAL27862 had a low apparent clearance (CL/F: 10.1 L/h) and
moderate apparent volume of distribution (Vz/F: 182 L), resulting
in a half-life of 12.6 h.
Urinary excretion was not a significant route of elimination with
<0.1% of the administered dose of BAL101553 and <1% of the
equivalent dose for BAL27862 recovered in the urine (Supple-
mentary Table 3). The PK parameters for BAL101553 and
BAL27862 on day 1, cycle 1 are shown in Table 3 and
Supplementary Table 4. The curves for all cohorts and PK days
are shown in Supplementary Figs. 2A, B, 3.
Pharmacokinetic/adverse reaction relationships. A dose relation-
ship was observed for nausea/vomiting, transient arterial hyper-
tension, peripheral sensory neuropathy, and pain at tumour site.
Arterial hypertension was significantly higher in patients treated
with 60–80mg/m2 BAL101553 than at 15–30mg/m2 (Fig. 1c) and
subsided over the course of several hours after the end of the 2-h
intravenous study-drug administration. Peak blood pressure
elevations occurred when the concentrations of the active drug
BAL27862 were highest (during the first hours after the end of the
2-h infusion).
Pharmacodynamics
Functional MRI was conducted in eight (11.0%) patients, six of
whom had complete datasets and were evaluable (five treated at
30mg/m2 and one at 45 mg/m2). There was no significant
difference in cohort mean values for Ktrans (volume transfer
constant; p= 0.95), IAUGC60 (the integrated area under the
gadolinium curve in tissue over 60 s; p= 0.93) and the Apparent
Diffusion Coefficient (p= 0.92) across the five imaging time points,
suggesting no observable treatment effect on dynamic contrast-
enhanced MRI and diffusion-weighted MRI parameters within this
cohort.
Table 1. Baseline demographic and disease history data of the 73
enrolled and treated patients.
Total (n= 73)
Age (years), median (range) 59.0 (29–80)
Female/Male, n (%) 34 (46.6)/39 (53.4)
ECOG PS 0/1, n (%) 23 (31.5)/50 (68.5)
Prior treatment regimens
Overall, median (range) 3 (0–8)
Chemotherapy/hormone therapy, n (%) 72 (98.6)
Prior MTAs, n (%) 34 (46.6)
Radiotherapy, n (%) 29 (39.7)
Surgery, n (%) 52 (71.2)
Most common tumour types
Colorectal 22 (30.1)
NSCLC 9 (12.3)
Pancreatic/ampullary cancer 9 (12.3)
Gastro-oesophageal cancer 8 (11.0)
Ovarian/primary peritoneal cancer 8 (11.0)
TNBC 4 (5.5)
Othera 13 (17.8)
Tumour histology, n (%)
Adenocarcinoma 59 (80.8)
Squamous cell carcinoma 3 (4.1)
Other 11 (15.1)
Metastatic disease, n (%) 66 (91.7)
Histopathological grade, n (%)
Grade 1 0
Grade 2 24 (33.8)
Grade 3 19 (26.8)
Not assessable 16 (22.5)
Other 12 (16.9)
Missing 2
ECOG PS Eastern Cooperative Oncology Group performance status, MTA
microtubule-targeting agent, NSCLC non-small-cell lung cancer, TNBC triple-
negative breast cancer.
aOther comprises: two cases of oesophageal cancer and single cases of
adrenocortical cancer, anal cancer, cervical cancer, cholangiocellular
cancer, epitheliod mesothelioma, gastric cancer, laryngeal cancer,
mesenchymal chondrosarcoma, neuroendocrine cancer, small bowel
cancer, thymoma.
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Fig. 1 Pharmacokinetic profile of BAL27862 following adminis-
tration of the prodrug BAL101553. BAL27862 exposure (a Cmax and
b AUCinf) and c mean change from baseline in systolic blood
pressure according to BAL101553 dose at cycle 1, day 1 (N= 73). Box
plots in (a, b) show median (solid horizontal line), mean (dashed
horizontal line), interquartile range (box), 1.5 times the interquartile
range (whiskers), and outliers (circles). Error bars in (c) indicate 95%
confidence intervals.
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Twenty-four patients provided 1–3 pre- and post-treatment
biopsies (median= 2). Evaluable pairs of pre- and post-treatment
biopsies were available from six patients. Reductions in tumour
microvascular density (five patients, based on CD34 staining) and/
or decreases in tumour cell proliferation (two patients, based on
Ki67 staining) were apparent (Supplementary Table 5 and
Supplementary Figs. 4, 5). There was no clear dose effect
regarding the change from baseline in enumerations of circulating
tumour cells, circulating endothelial cells, or circulating endothe-
lial progenitor cells.
Efficacy
Overall, 57 (78.1%) patients were evaluable for efficacy. One
patient with an ampullary carcinoma had a PR (starting dose level
of 30 mg/m2 with subsequent dose escalation to 45 mg/m2). This
PR lasted for over 2 years. The ORR was therefore 1.8% (95% CI:
0.0, 9.4). Fourteen (24.6%) other patients had SD lasting two or
more cycles (median 15 weeks; range 7–33) as the best response
(including four with SD lasting for four or more cycles), leading to
an overall DCR of 26.3% (95% CI: 15.5, 39.7; n= 15). The overall
median PFS was 50.0 days (95% CI: 50.0, 51.0). The PR, SD, and
progressive disease rates in patients who received BAL101553 at
the recommended phase 2 dose of 30 mg/m2 (n= 36) were 3.2%,
16.1%, and 80.6%, respectively, equating to an ORR of 3.2% (95%
CI: 0.1, 16.7) and a DCR of 19.4% (95% CI: 7.5, 37.5) in these
patients. There was no apparent relationship between tumour
type and response. Overall, four of 53 (7.5%) evaluable patients
had reductions in the sum of longest diameter from baseline for
target lesions at least once during the study. These comprised the
patient with ampullary carcinoma (target lesion: mesenteric lymph
node; −73.3% change) and a patient with pancreatic cancer (two
target lesions: liver, −22.6% change) treated at 30 mg/m2; a
patient with NSCLC (two target lesions: lung, −1.3% change)
treated at 45 mg/m2; and a patient with cervical cancer (target
lesion: hilar lymph node, −12.5% change) treated at 60 mg/m2.
The overall median maximum change in the sum of longest
diameter from baseline was 17.9% (range −73.3 to 171%; Fig. 2).
There was no clear difference in efficacy between patients with/
without prior MTA treatment. The patient with ampullary
carcinoma who had a PR had not had prior MTA treatment.
DISCUSSION
This was a two-part open-label study in patients with solid
tumours designed to determine the MTD and DLT of a 2-h infusion
of BAL101553, the lysine prodrug of BAL27862, and to investigate
the overall safety tolerability, PK profile, and anti-tumour activity.
The primary objective of the study was met by establishing the
MTD for BAL101553 as initially 60 mg/m2 when administered
intravenously over 2 h as single agent on days 1, 8, and 15 of a 28-
day treatment cycle. The RP2D was determined as 30mg/m2.
The DLTs were reversible Grade 2–3 gait disturbance at dose
levels ≥60mg/m2, occurring with Grade 2 peripheral sensory
neuropathy and asymptomatic myocardial injury at dose levels
≥45mg/m2. Most of the Grade 3 neurological events and all
cardiac events occurred during or after the first infusion of study
Table 3. Summary of BAL27862 PK parameters for cycle 1, day 1 across dose cohorts.
Arm Tmax
(h)
Cmax
(ng/mL)
Cmax/dose
(ng/mL/mg)
AUClast
(h × ng/mL)
T1/2
(h)
AUCinf
(h × ng/mL)
CL/F
(mL/h)
Vz/F
(mL)
15mg/m2
N Obs 1 1 1 1 1 1 1 1
Mean 2.5 154 9.62 1810 18.1 2110 7610 199,000
Geometric mean 2.5 154 9.62 1810 18.1 2110 7610 199,000
CV% geometric mean — — — — — — — —
30mg/m2
N Obs 36 36 36 36 36 36 36 36
Mean 2.17 271 7.5 2680 14.4 4150 11,500 200,000
Geometric mean 2.13 267 7.3 2530 12.6 3620 10,100 183,000
CV% geometric mean 16.7 19.8 24.1 35.3 57.2 55.7 58.7 41.3
45mg/m2
N Obs 8 8 8 8 8 8 8 8
Mean 2.39 356 7.02 4340 13.6 5770 12,000 190,000
Geometric mean 2.3 346 6.8 3960 12.5 5090 10,000 180,000
CV% geometric mean 28.8 26.3 29.2 51.9 47.7 62.9 67 33.7
60mg/m2
N Obs 21 21 21 21 21 21 21 21
Mean 2.41 498 6.98 6040 14.3 7920 10,600 206,000
Geometric mean 2.34 484 6.79 5580 13.8 7180 9910 197,000
CV% geometric mean 23.8 25.1 25 39.7 26.5 44.5 41 32.8
80mg/m2
N Obs 7 7 7 7 7 7 7 7
Mean 2.35 606 6.28 7760 12.9 8560 12,700 227,000
Geometric mean 2.33 601 6.25 7330 12.5 7950 12,100 218,000
CV% geometric mean 14.3 13.1 11 36.2 26.7 40.5 35.8 31.2
AUCinf area under the curve from time zero to infinity, AUClast area under the curve from time zero to last measurable concentration, CL/F apparent clearance,
Cmax maximum concentration, CV% percentage of coefficient of variation, T1/2 terminal half-life, Tmax time taken to reach Cmax, Vz/F apparent volume of
distribution in terminal phase.
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drug and appeared to be related to the Cmax of BAL101553/
BAL27862.
Peripheral neuropathy is common with MTA therapy due to
their axonal microtubule disrupting activity.2,5,22 In this study,
Grade 2 peripheral sensory neuropathy with reduced propriocep-
tion/sensation was observed in two patients treated with 80mg/
m2 BAL101553 and contributed to the DLTs of Grade 2–3 gait
disturbance in these patients. At the RP2D (30 mg/m2), the
incidence of Grade 1/2 peripheral neuropathy was relatively low
(5.6%) and reversible, and no instances of Grade 3/4 peripheral
neuropathy were reported. Furthermore, the incidences of other
nervous system disorders commonly associated with MTA therapy,
such as headache and dizziness,3 were low following treatment
with BAL101553.
Cardiovascular toxicity was not seen in standard non-clinical
toxicity studies including a telemetered dog study. However,
several study-design changes were required to reflect the dose-
related cardiac and vascular effects observed during the study and
non-clinical data which arose while the study was ongoing that
indicated a dose-related vascular-disrupting effect of BAL101553
in animal models. The changes to the protocol resulted in lower
doses of BAL101553 being investigated in the phase 2a part of the
study. The dose in the MTD-arm was reduced to 45mg/m2 and
then to 30mg/m2, following the observation of clinical cardiovas-
cular toxicity in three patients. The three instances of asympto-
matic myocardial injury at dose levels ≥45mg/m2 were
interpreted as microvascular myocardial damage due to the
vascular-disrupting properties of BAL101553/BAL27862. The inci-
dence and the time course of blood pressure elevations provide
further evidence for a Cmax-related vascular-disrupting effect of
BAL101553. Rises in blood pressure predominantly occurred at
dose levels ≥45mg/m2. These elevations were transient and
generally resolved within 24 h following the intravenous dose.
Blood pressure elevations were uncommon in patients treated at
doses of 15–30mg/m2. The early occurrence of troponin eleva-
tions (peak levels were observed at 8 h after the end of infusion) is
also consistent with a Cmax-related vascular effect, as is the
reduction in the number of tumour microvessels in paired (pre- vs.
post-dose) tumour biopsies. BAL101553 appears to be inducing
significant microvascular changes, which may also explain the
increasing occurrence of certain AEs such as hypertension with
increasing dose.
Systemic side effects of BAL101553 that showed a clear dose
relationship included nausea/vomiting, transient arterial hyperten-
sion, peripheral sensory neuropathy, gait disturbance, myocardial
ischaemia/infarction, and possibly abdominal/tumour-related
pain. These side effects were absent or clinically not relevant at
dose levels of up to 30 mg/m2 but occurred with a low prevalence
at the dose level of 45mg/m2 and a high prevalence at the dose
levels of 60 and 80mg/m2. Events observed at the higher dose
levels usually required clinical monitoring, additional diagnostic
measures, and occasionally, dose reductions or study drug
discontinuation (for peripheral neuropathy, gait disturbance, and
myocardial injury) and therapeutic interventions (including
antiemetic, antihypertensive treatment, analgesic treatment, or
cardiac treatment equivalent to the treatment of an acute
coronary syndrome). Additional systemic side effects considered
characteristic of BAL101553, but which did not show a clear dose
relationship, included anorexia, diarrhoea, fatigue, and pyrexia.
The incidence of gastrointestinal disturbances with BAL101553,
namely nausea, vomiting and diarrhoea, and fatigue, was in
keeping with those of other MTAs, particularly at doses above 30
mg/m2.3 Myeloid toxicity, particularly neutropenia, is a common
and often severe side effect observed in MTA-based combination
regimens.2 No AEs of neutropaenia were reported with BAL101553
in this study. The only blood/lymphatic system disorder observed
Colorectal
Gastro-oesophageal cancer
Non-small cell lung cancer
Other
Ovarian/primary peritoneal
Pancreatic/ampullary
Triple-negative breast cancer
15 mg/m2
80 mg/m2
200
150
100
50
0
–50
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45 mg/m2 60 mg/m230 mg/m2
Fig. 2 Waterfall plot of best percentage change from baseline in sum of longest diameter for target lesions (N= 53 evaluable patients).
Upper dotted line indicates the RECIST v1.1 criteria for progressive disease; lower dotted line indicates the RECIST v1.1 criteria for partial
response.
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was Grade 1−2 anaemia, occurring at a very low incidence (9.6%)
and appearing to be unrelated to BAL101553 dose.
Overall, the RP2D of 30 mg/m2 determined in this study was
well tolerated and showed signals of anti-tumour activity. The only
Grade 3 drug-related toxicities at this level were fatigue and rare
cases of transient hypertension (in patients with pre-existing
hypertension). No relevant, drug-related neurological or cardiac
toxicities were observed and there were only small effects on
blood pressure. At this dose, with the largest number of patients
(n= 36 on cycle 1, day 1), PK exposure showed low to moderate
variability with geometric mean CV% of <20% for Cmax and <60%
for AUCinf.
The single PR in the patient with an ampullary carcinoma
treated at 30mg/m2 and escalated to 45 mg/m2 was long lasting.
The PR response occurred at the starting dose level of 30 mg/m2
and this patient remained on treatment for 36 cycles before
discontinuing due to the development of an allergic reaction to
the study drug.
The 2-h intravenous dosing strategy is no longer being
pursued; however, further investigation of BAL101553 is
underway, exploring alternative dosing strategies to minimise
the Cmax-related vascular toxicity, including oral dosing
(EudraCT 2014-003371-34, NCT02490800) and administration
as a 48-h continuous infusion (NCT0289536023). Encouraging
data have been reported on the use of BAL101553 in
combination with radiotherapy in paclitaxel and epothilone-
resistant14 and orthotopic glioblastoma19 tumour models. A
study of BAL101553 in combination with radiation therapy in
patients with newly diagnosed glioblastoma (NCT03250299) is
currently underway, and further investigations in patients with
ovarian cancer and in patients with recurrent glioblastoma are
planned.
In conclusion, BAL101553 is a novel spindle assembly check-
point controller with both anti-proliferative and vascular-
disrupting effects. BAL101553 given weekly as a 2-h infusion
exhibited dose-limiting neurological and cardiovascular effects at
dose levels ≥45mg/m2 that appear to be related to maximum
plasma concentration. The recommended phase 2 dose of 30 mg/
m2 was well tolerated and showed preliminary signals of anti-
tumour activity.
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